本帖最后由 老马 于 2012-1-13 21:20 编辑
. N* r% j% ^7 f) O/ e8 v/ b l( P
爱必妥和阿瓦斯丁的比较
% Z: `9 q% a, t. q1 M3 ^
- f% L0 M; i q" y# Y
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
/ }8 y o5 D8 T) E0 T. U/ I
+ a5 j% J6 y- }4 P* N0 Q
: J$ y+ p) w8 Z; q9 F# z2 i9 z; Vhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
5 x( {6 C! f) m7 V0 V==================================================
5 `4 r; Z( d5 N& z) D3 KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
" A7 o8 \! h/ k! }1 f( {) C# qPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 C9 M5 y, o0 MResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* f& x1 M; l S5 d- F4 E% B
|